Nova Eye Medical Limited (ASX:EYE)
Australia · Delayed Price · Currency is AUD 0.1250
-0.0050 (-4.00%)
Apr 7, 2026, 3:51 PM AEST
Nova Eye Medical Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Revenue | 33.05 | 29.27 | 23.33 | 17.03 | 13.38 | 13.39 |
| 33.05 | 29.27 | 23.33 | 17.03 | 13.38 | 13.39 | |
Revenue Growth (YoY) | 26.59% | 25.47% | 37.00% | 27.26% | -0.12% | 4.51% |
Cost of Revenue | 11 | 10.38 | 6.5 | 2.63 | 2.29 | 2.24 |
Gross Profit | 22.05 | 18.89 | 16.83 | 14.39 | 11.09 | 11.15 |
Selling, General & Admin | 20.85 | 19.63 | 16.8 | 21.87 | 17.4 | 13.21 |
Research & Development | 3.17 | 3.24 | 3.97 | - | - | - |
Other Operating Expenses | 5.1 | 5 | 5.03 | 2.01 | 1.58 | 1.39 |
Operating Expenses | 29.12 | 27.87 | 25.8 | 26.17 | 20.79 | 16.12 |
Operating Income | -7.07 | -8.99 | -8.97 | -11.78 | -9.7 | -4.97 |
Interest Expense | -0.18 | -0.16 | -0.07 | -0.05 | -0.06 | -0.07 |
Interest & Investment Income | 0.09 | 0.08 | 0.12 | 0.1 | 0.03 | 0.24 |
Currency Exchange Gain (Loss) | - | - | - | 0.14 | -0.05 | -0.48 |
Other Non Operating Income (Expenses) | 0.14 | - | 0.13 | 0.63 | 0.54 | 0.03 |
EBT Excluding Unusual Items | -7.03 | -9.06 | -8.79 | -10.96 | -9.24 | -5.25 |
Asset Writedown | - | - | - | -6.04 | - | - |
Other Unusual Items | - | - | - | - | 1.42 | - |
Pretax Income | -7.03 | -9.06 | -8.79 | -17 | -7.82 | -5.25 |
Income Tax Expense | - | - | - | -1.71 | -0.32 | -0.89 |
Earnings From Continuing Operations | -7.03 | -9.06 | -8.79 | -15.29 | -7.5 | -4.36 |
Net Income | -7.03 | -9.06 | -8.79 | -15.29 | -7.5 | -4.36 |
Net Income to Common | -7.03 | -9.06 | -8.79 | -15.29 | -7.5 | -4.36 |
Shares Outstanding (Basic) | 275 | 247 | 204 | 156 | 145 | 144 |
Shares Outstanding (Diluted) | 275 | 247 | 204 | 156 | 145 | 144 |
Shares Change (YoY) | 23.07% | 21.16% | 30.89% | 7.83% | 0.69% | 0.03% |
EPS (Basic) | -0.03 | -0.04 | -0.04 | -0.10 | -0.05 | -0.03 |
EPS (Diluted) | -0.03 | -0.04 | -0.04 | -0.10 | -0.05 | -0.03 |
Free Cash Flow | -5.21 | -6.45 | -8.07 | -7.09 | -4.85 | -13.53 |
Free Cash Flow Per Share | -0.02 | -0.03 | -0.04 | -0.04 | -0.03 | -0.09 |
Gross Margin | 66.71% | 64.54% | 72.15% | 84.55% | 82.89% | 83.25% |
Operating Margin | -21.40% | -30.70% | -38.47% | -69.19% | -72.50% | -37.07% |
Profit Margin | -21.27% | -30.95% | -37.69% | -89.83% | -56.03% | -32.52% |
Free Cash Flow Margin | -15.77% | -22.03% | -34.59% | -41.63% | -36.27% | -100.99% |
EBITDA | -4.88 | -6.72 | -5.98 | -9.48 | -7.89 | -3.45 |
EBITDA Margin | -14.77% | -22.97% | -25.66% | -55.69% | -58.96% | -25.76% |
D&A For EBITDA | 2.19 | 2.26 | 2.99 | 2.3 | 1.81 | 1.52 |
EBIT | -7.07 | -8.99 | -8.97 | -11.78 | -9.7 | -4.97 |
EBIT Margin | -21.40% | -30.70% | -38.47% | -69.19% | -72.50% | -37.07% |
Advertising Expenses | - | - | - | 3.2 | 1.78 | 0.73 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.